VOYA:NYSEVoya Financial, Inc. Analysis
Data as of 2026-07-30 - not real-time
$100.27
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Voya Financial is trading above its 20‑day and 50‑day simple moving averages, while still below the 200‑day SMA, indicating a short‑term bullish bias within a longer‑term uptrend. RSI sits near 65, suggesting momentum remains strong but is not yet in overbought territory. The MACD shows a bearish histogram, hinting at a possible near‑term pullback, yet the price remains well above the identified support around $93. Volume has been decreasing, which could limit upside momentum but also reflects a more stable trading environment. The DCF‑derived fair value of roughly $196 is nearly double the current market price, implying a substantial undervaluation with an upside potential of about 4% according to the model. Dividend yield close to 2% and a modest payout ratio reinforce cash‑flow comfort.
Analyst consensus is a “buy” with a median target near $106, and the forward PE of under 9x positions Voya as a value‑oriented play despite modest revenue growth. The company’s low beta (~0.8) and a 30‑day volatility around 20% suggest limited price swings relative to the market. Recent news of a declared common‑stock dividend underscores confidence in cash generation. Overall, the blend of technical support, attractive valuation gaps, and sustainable dividend income makes Voya a compelling candidate for investors seeking upside with limited downside.
Analyst consensus is a “buy” with a median target near $106, and the forward PE of under 9x positions Voya as a value‑oriented play despite modest revenue growth. The company’s low beta (~0.8) and a 30‑day volatility around 20% suggest limited price swings relative to the market. Recent news of a declared common‑stock dividend underscores confidence in cash generation. Overall, the blend of technical support, attractive valuation gaps, and sustainable dividend income makes Voya a compelling candidate for investors seeking upside with limited downside.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above 20‑day SMA indicating short‑term bullish momentum
- Support level near $93 providing downside cushion
- Attractive dividend yield with low payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to DCF fair value
- Forward PE under 9x suggesting strong earnings upside
- Stable cash flow and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term uptrend above 200‑day SMA
- Low beta and moderate volatility limiting systematic risk
- Consistent earnings growth and strong balance‑sheet metrics
Key Metrics & Analysis
Financial Health
Revenue Growth3.10%
Profit Margin8.24%
P/E Ratio15.1
ROE11.89%
ROA0.42%
Debt/Equity73.44
P/B Ratio2.0
Op. Cash Flow$1.4B
Free Cash Flow$1.5B
Industry P/E18.1
Technical Analysis
TrendBullish
RSI65.5
Support$93.37
Resistance$103.85
MA 20$98.11
MA 50$91.43
MA 200$77.96
MACDBearish
VolumeDecreasing
Fear & Greed Index90.91
Valuation
Fair Value$196.47
Target Price$104.25
Upside/Downside3.97%
GradeUndervalued
TypeValue
Dividend Yield1.88%
Risk Assessment
Beta0.79
Volatility20.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.